Screener
Agios Pharmaceuticals AGIO Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $16,345 | $18,355 |
| Accrued expenses | 34,647 | 45,459 |
| Operating lease liabilities | 19,225 | 18,392 |
| Total current liabilities | 70,217 | 82,206 |
| Operating lease liabilities, net of current portion | 11,946 | 21,815 |
| Other non-current liabilities | 240 | 90 |
| Total liabilities | 82,403 | 104,111 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's operating lease liabilities (current)?
- Agios Pharmaceuticals (AGIO) reported operating lease liabilities (current) of $19.23M in Q2 2026.
- How has Agios Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Agios Pharmaceuticals's operating lease liabilities (current) increased by 9.3% year-over-year, from $17.59M to $19.23M.
- What is the long-term trend for Agios Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's operating lease liabilities (current) has grown at a 21.0% compound annual growth rate (CAGR), from $7.09M to $18.39M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Agios Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude